Innate Pharma Advances Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing To Phase 2 For Blood Cancer Patients
Innate Pharma 推動賽諾菲開發的 NK Cell Engager SAR443579/IPH6101 進入第二階段,用於血癌患者
Innate Pharma Advances Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing To Phase 2 For Blood Cancer Patients
Innate Pharma 推動賽諾菲開發的 NK Cell Engager SAR443579/IPH6101 進入第二階段,用於血癌患者
使用瀏覽器的分享功能,分享給你的好友吧